Fresenius API Facility Receives FDA Warning

Fresenius API Facility Receives FDA Warning
Fresenius Kabi has received a warning letter from the FDA regarding its API facility in India.

The letter, dated July 1, related to an inspection made by the US Food and Drug Administration (FDA) in January 2013 where a number of GMP (Good Manufacturing Practice) non-conformities were observed at the firm’s oncolytic API plant in Kalyani, India.

An official statement​ by Fresenius said the firm “has made significant progress in remedying the issues cited in the Warning Letter”​ and the process of restarting manufacturing at the facility – following a precautionary halt in production following the inspection - has begun, based on a remediation plan submitted to the FDA.

Last news comes just a week after the firm issued a voluntary recall​ of four lots of Benztropine Mesylate Injection due to the potential presence of glass particles.The drug was manufactured by Allergy Laboratories on behalf of Fresenius. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars